3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
6
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Astrocytoma
2
Vipoma
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Progression Free Survival
1
Oropharyngeal Neoplasms
1
Oesophagogastric Cancer
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Mesothelioma
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Insulinoma
1
Inflammatory Breast Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Paclitaxel
2
Letrozole
1
Lapatinib
1
Gonadotropin-Releasing Hormone
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Ductal, Breast
×
Bevacizumab
×
Clear all
NCT01426880
2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3
Completed
595 enrolled